Press releases
- Soligenix Announces Reverse Stock Split
- Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting
- Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
- Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split
- SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference
- Soligenix Encourages Stockholders to Vote Prior to Annual Meeting
- Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice
- Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results
- Soligenix to Present at Upcoming Conferences
- Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa
More ▼
Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 0.00 |
Low | 0.00 |
Bid | -- |
Offer | -- |
Previous close | 0.3729 |
Average volume | -- |
---|---|
Shares outstanding | 15.80m |
Free float | 15.79m |
P/E (TTM) | -- |
Market cap | 5.53m USD |
EPS (TTM) | -0.7395 USD |
Data delayed at least 15 minutes, as of Feb 10 2023.
More ▼